Table 1 Number of families, patients with cutaneous malignant melanoma and families with CDKN2A mutations by study centre and summarised by country/continent and overall (total).
| Centre | Country/continent | Total number of families | Total number of patients with CMM | Number of families with CDKN2A mutations | References for family ascertainment |
|---|---|---|---|---|---|
| Boston | USA/North America | 3 | 9 | 0 | 18 |
| Leeds | USA/North America | 1 | 3 | 0 | 29 |
| NCI | USA/North America | 38 | 192 | 19 | 19,20 |
| Philadelphia | USA/North America | 5 | 18 | 1 | |
| Utah | USA/North America | 11 | 150 | 5 | 21 |
| Toronto | Canada/North America | 7 | 22 | 4 | |
| North America | 65 | 394 | 29 | ||
| Barcelona | Spain/Europe | 11 | 38 | 5 | 22,23,24,25 |
| Emilia‐Romagna | Italy/Europe | 8 | 27 | 1 | 26 |
| Genoa | Italy/Europe | 8 | 31 | 5 | 11 |
| Glasgow | Scotland/Europe | 10 | 31 | 6 | 9,27 |
| Leeds | England/Europe | 29 | 107 | 22 | 28,29,30 |
| Leiden | The Netherlands/Europe | 26 | 154 | 19 | 31,32 |
| Paris | France/Europe | 40 | 133 | 19 | 6,33,34 |
| Lund | Sweden/Europe | 15 | 60 | 8 | 12,35 |
| Stockholm | Sweden/Europe | 10 | 36 | 4 | 36,37,38 |
| Europe | 157 | 617 | 89 | ||
| Brisbane | Australia | 100 | 446 | 18 | 39,40,41,42 |
| Sydney | Australia | 62 | 258 | 14 | 10,28,43,44 |
| Australia | 162 | 704 | 32 | ||
| Tel‐Aviv | Israel/Asia | 1 | 5 | 0 | |
| Total | 385 | 1720 | 150 |
CMM, cutaneous malignant melanoma.